Compare ON Semiconductor (ON) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Semiconductor vs Spyre Therapeutics Inc. Common Stock — how do they compare? ON Semiconductor trades at $72.02 (market cap $29.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: ON Semiconductor is far larger — about 4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ON Semiconductor nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Semiconductor for 7 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ON | SYRE | |
|---|---|---|
Market Cap | $29.86B | $7.52B |
Volume | 7,140,901 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $133.93 | $108.92 |
52-Week Low | $44.90 | $22.18 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $30.48B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ON Semiconductor (ON) trades at $76.69, up 0.91% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with 9% revenue growth and significant EPS expansion, while analyst consensus remains positive with a $100 price target. Recent news highlights the revised Synaptics acquisition and AI infrastructure opportunities.
The stock presents a turnaround story with improving profitability and AI growth potential, though technical weakness and competitive pressures warrant caution. Upside catalysts include margin expansion and data center demand, while risks include integration challenges from the Synaptics deal and semiconductor cycle volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ON Semiconductor
Onsemi develops power and sensing semiconductors for automotive, industrial, and energy applications. Its products support functions such as electric vehicle systems, energy conversion, automation, and intelligent sensing.
Read more on ON →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
